share_log

Naya Biosciences To Acquire Florida Biotechnologies For $20M Shares Of NAYA Post-Merger With INVO; Florida Biotechnologies Eligible For Additional $5M Upon Certain Milestones Achievement

moomoo News ·  Jan 23 08:47
  • NAYA to accelerate Phase II clinical development and Early Patient Access after initial safety demonstrated in 28-patient clinical trial
  • Program developed by Florida Biotechnologies, Inc. & the University of Miami's Bascom Palmer Eye Institute
  • NAYA continuing to implement acquisition roll-up of clinical and commercial assets in oncology, regenerative medicine, and fertility
  • NAYA expects to close its previously announced merger with INVO Bioscience (NASDAQ: INVO) in the first quarter of 2024 following the recent filing of S-4 and joint draft proxy statements
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment